Atossa Therapeutics Inc Stock Price, News & Analysis

Atossa Therapeutics (Nasdaq: ATOS) urges stockholders to participate in voting for proposals in its proxy statement ahead of the annual stockholder meeting on May 14, 2021. As of March 24, 2021, approximately 17.3 million shares are under lock-up and voting agreements. The company focuses on developing innovative treatments for unmet medical needs in oncology and infectious diseases, particularly breast cancer and COVID-19. For more information on voting and proposals, stockholders can refer to the proxy statement linked in the announcement.

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical firm, announced participation by CEO Dr. Steven Quay in a panel discussion at Cello Health's Cancer Progress Virtual Conference on May 6, 2021, at 10:00 AM ET. The panel, titled 'Investing in the Emerald City of Oncology Innovation,' will include experts from various venture investment funds. Atossa focuses on developing innovative treatments for oncology and infectious diseases, particularly breast cancer and COVID-19. For registration, visit their official site.

Atossa Therapeutics (Nasdaq: ATOS) announces an ovarian cancer patient has started treatment with its proprietary oral Endoxifen, following FDA approval via the expanded access pathway. This patient, treated by Dr. Barbara Goff at the University of Washington, previously did not tolerate tamoxifen. Molecular testing indicated that Endoxifen combined with alpelisib yielded a significant tumor response. The FDA's expanded access allows use solely for this patient, and Atossa is considering additional clinical studies.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported its 2020 financial results, highlighting significant advancements in its clinical programs, particularly for Endoxifen and AT-301. The company concluded a Phase 2 study for Endoxifen early due to positive interim results, accelerated its development plans, and received FDA approval for expanded access in ovarian cancer treatment. Operating expenses declined 15% to approximately $14.6 million, with R&D expenses slightly decreasing. At year-end, Atossa held about $39.7 million in cash, positioning itself well for future opportunities.

On March 30, 2021, Dr. Steven Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), published an Open Letter addressing the WHO report, emphasizing evidence supporting the lab origin of COVID-19. The letter outlines five undisputed facts indicating the likelihood of a laboratory-acquired infection. Dr. Quay calls for recognition of these facts to prevent future pandemics. He has shared the letter with over thirty global scientists, including WHO investigators, and advocates for a moratorium on gain-of-function research to avoid similar crises.

Atossa Therapeutics (Nasdaq: ATOS) announced a registered direct offering of $50 million in common stock and warrants priced at $2.88 per share. The agreement involves the sale of 17,361,100 shares and unregistered warrants for an additional 13,020,825 shares with a four-and-a-half-year expiration period. The offering, expected to close on March 24, 2021, is facilitated by Maxim Group LLC. Proceeds will support the company's clinical-stage operations focusing on oncology and infectious diseases. This move may impact shareholder equity through potential dilution.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that the FDA issued a "Safe to Proceed" letter allowing the use of their oral Endoxifen as a treatment for a patient with recurrent ovarian cancer. The treatment is being conducted at the University of Washington Medical Center by Dr. Barbara Goff. The patient's tumor responded well to a combination of Endoxifen and alpelisib, prompting Atossa to consider further clinical studies if successful.

Endoxifen, an active metabolite of tamoxifen, has shown significant efficacy in preclinical studies.

Atossa Therapeutics (Nasdaq: ATOS) released final results from its Phase 1 trial of AT-301, a nasal spray for COVID-19, indicating the treatment was safe and well-tolerated. Conducted on 32 healthy participants, the trial noted no serious adverse events, with only one case of moderate adverse events. The company plans to begin a pre-clinical study this quarter and aims to initiate a Phase 2 study in the U.S. AT-301 may also serve as a preventive measure against COVID-19, particularly in high-risk environments. The mechanism of AT-301 targets viral entry, suggesting potential effectiveness against variants.

Atossa Therapeutics (Nasdaq: ATOS) has provided an update on its progress amid the COVID-19 pandemic. The company raised approximately $81 million in net proceeds, enabling continued development in oncology and infectious diseases. Key developments include:

• AT-301 Nasal Spray for COVID-19, with Phase 1 study data expected in Q1 2021.
• AT-H201 Inhalation Therapy showing potential in clinical tests.
• Oral Endoxifen demonstrating significant tumor cell proliferation reduction.

Atossa's commitment to innovative therapies remains strong.